Long-term functioning and sleep quality in patients with major depressive disorder treated with extended-release quetiapine fumarate

International Clinical Psychopharmacology

Volumn 27, Issue 5, 2012, Pages 239-248

  Sheehan, David V ^a   Locklear, Julie ^b   Svedsäter, Henrik ^c   Datto, Catherine ^b  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

^b ASTRAZENECA   (United Kingdom)

^c ASTRAZENECA R AND D   (Sweden)

Author keywords

extended release quetiapine fumarate; long term functioning; major depressive disorder; sleep quality

Indexed keywords

PLACEBO; QUETIAPINE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; FEMALE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MONOTHERAPY; PITTSBURGH SLEEP QUALITY INDEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; SHEEHAN DISABILITY SCALE; SLEEP QUALITY; SOMNOLENCE; SUSTAINED DRUG RELEASE;

ACTIVITIES OF DAILY LIVING; ADOLESCENT; ADULT; AGED; ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; DELAYED-ACTION PREPARATIONS; DEPRESSIVE DISORDER, MAJOR; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIBENZOTHIAZEPINES; DOUBLE-BLIND METHOD; DRUG MONITORING; FEMALE; HUMANS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; RECURRENCE; SLEEP DISORDERS; YOUNG ADULT;

EID: 84864680306     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0b013e328356ac78     Document Type: Article

References (40)

1. Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, et al. (2004). Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand (Suppl 420):21-27.
2. American Psychiatric Association (2000). Diagnostic and statistical manual of mental disorders. 4th ed, Text Revision. Washington, DC: American Psychiatric Association.
3. Bauer M, Pretorius HW, Constant EL, Earley WR, Szamosi J, Brecher M (2009). Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry 70:540-549.
4. Birnbaum HG, Kessler RC, Kelley D, Ben-Hamadi R, Joish VN, Greenberg PE (2010). Employer burden of mild, moderate, and severe major depressive disorder: mental health services utilization and costs, and work performance. Depress Anxiety 27:78-89.
5. Bortnick B, El-Khalili N, Banov M, Adson D, Datto C, Raines S, et al. (2011). Efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in major depressive disorder: a placebo-controlled, randomized study. J Affect Disord 128:83-94.
6. Buysse DJ, Reynolds CF III, Monk TH, Berman SR, Kupfer DJ (1989). The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 28:193-213. (Pubitemid 19144991)
7. Calabrese JR, Keck PE Jr, Macfadden W, Minkwitz M, Ketter TA, Weisler RH, et al. (2005). A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry 162:1351-1360. (Pubitemid 40905587)
8. Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Aström M, Brecher M (2009). Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo-and duloxetine-controlled study. J Clin Psychiatry 70:526-539.
9. El-Khalili N, Joyce M, Atkinson S, Buynak R, Datto C, Lindgren P, et al. (2010). Extended-release quetiapine fumarate (quetiapine XR) as adjunctive therapy in major depressive disorder (MDD) in patients with an inadequate response to ongoing antidepressant treatment: a multicentre, randomized, doubleblind, placebo-controlled study. Int J Neuropsychopharmacol 13:917-932.
10. Endicott J, Paulsson B, Gustafsson U, Schioler H, Hassan M (2008). Quetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleep. J Affect Disord 111:306-319.
11. Fabian Z, Karanyi Z, Szadoczky E (2005). The impact of antidepressive therapy on work productivity and life satisfaction-a one-year follow-up study. Neuropsychopharmacol Hung 7:146-156.
12. Gabilondo A, Rojas-Farreras S, Vilagut G, Haro JM, Fernandez A, Pinto-Meza A, et al. (2010). Epidemiology of major depressive episode in a southern European country: results from the ESEMeD-Spain project. J Affect Disord 120:76-85.
13. Guy W (1976). ECDEU assessment manual for psychopharmacology. Rockville, MD: US National Institute of Health.
14. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56-62.
15. Hasin DS, Goodwin RD, Stinson FS, Grant BF (2005). Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. Arch Gen Psychiatry 62:1097-1106. (Pubitemid 41396935)
16. Katila H, Mezhebovsky I, Mulroy A, Berggren L, Eriksson H, EarleyW, Datto C (2012). Randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with major depressive disorder. Am J Geriatr Psychiatry Epub ahead of print.
17. Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE (2005). Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593-602. (Pubitemid 40973434)
18. Lepine JP, Gasquet I, Kovess V, Arbabzadeh-Bouchez S, Negre-Pages L, Nachbaur G, et al. (2005). Prevalence and comorbidity of psychiatric disorders in the French general population. Encephale 31:182-194. (Pubitemid 40675702)
19. Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Eriksson H (2010). Efficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety 27:964-976.
20. Mathers CD, Loncar D (2006). Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3:e442.
21. McElroy SL, Weisler RH, Chang W, Olausson B, Paulsson B, Brecher M, et al. (2010). A double-blind, placebo-controlled study of quetiapine and paroxetine as monotherapy in adults with bipolar depression (EMBOLDEN II). J Clin Psychiatry 71:163-174.
22. Mendlewicz J (2009). Sleep disturbances: core symptoms of major depressive disorder rather than associated or comorbid disorders. World J Biol Psychiatry 10:269-275.
23. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382-389. (Pubitemid 9136500)
24. Nemeroff CB (2007). Prevalence and management of treatment-resistant depression. J Clin Psychiatry 68 (Suppl 8):17-25. (Pubitemid 47184567)
25. Nierenberg AA, Husain MM, Trivedi MH, Fava M,Warden D,Wisniewski SR, et al. (2010). Residual symptoms after remission of major depressive disorder with citalopram and risk of relapse: a STARD report. Psychol Med 40:41-50.
26. Pratt LA, Brody DJ (2008). Depression in the United States household population, 2005-2006. NCHS Data Brief 1-8.
27. Rush AJ (2000). Handbook of psychiatric measures. Washington, DC: American Psychiatric Association.
28. Sheehan DV (1983). The anxiety disease. New York: Scribner.
29. Sheehan KH, Sheehan DV (2008). Assessing treatment effects in clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 23:70-83. (Pubitemid 351317279)
30. Sheehan DV, Harnett-Sheehan K, Raj BA (1996). The measurement of disability. Int Clin Psychopharmacol 11 (Suppl 3):89-95. (Pubitemid 26373761)
31. Sheehan DV, Harnett-Sheehan K, Spann ME, Thompson HF, Prakash A (2011). Assessing remission in major depressive disorder and generalized anxiety disorder clinical trials with the discan metric of the Sheehan Disability Scale. Int Clin Psychopharmacol 26:75-83.
32. Smit F, Cuijpers P, Oostenbrink J, Batelaan N, de Graaf R, Beekman A (2006). Costs of nine common mental disorders: implications for curative and preventive psychiatry. J Ment Health Policy Econ 9:193-200. (Pubitemid 46138516)
33. Suppes T, Datto C, Minkwitz M, Nordenhem A, Walker C, Darko D (2010). Effectiveness of the extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar depression. J Affect Disord 121:106-115.
34. Taylor DJ, Lichstein KL, Durrence HH, Reidel BW, Bush AJ (2005). Epidemiology of insomnia, depression, and anxiety. Sleep 28:1457-1464. (Pubitemid 41572796)
35. Thase ME, Macfadden W, Weisler RH, Chang W, Paulsson B, Khan A, et al. (2006). Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol 26:600-609. (Pubitemid 44772737)
36. Trivedi MH (2006). Major depressive disorder: remission of associated symptoms. J Clin Psychiatry 67 (Suppl 6):27-32. (Pubitemid 44078110)
37. Tsuno N, Besset A, Ritchie K (2005). Sleep and depression. J Clin Psychiatry 66:1254-1269. (Pubitemid 41546505)
38. Wang G, McIntyre A, Earley WR, Raines S, Eriksson H (2012). A randomized, double-blind study of the efficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Psychopharmacol Bull (in press).
39. Weisler R, Joyce M, McGill L, Lazarus A, Szamosi J, Eriksson H (2009). Extended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled study. CNS Spectr 14:299-313.
40. Young AH, McElroy SL, Bauer M, Philips N, Chang W, Olausson B, et al. (2010). A double-blind, placebo-controlled study of quetiapine and lithium monotherapy in adults in the acute phase of bipolar depression (EMBOLDEN I). J Clin Psychiatry 71:150-162.